-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The immune system protects the body from external factors.
, when the body's immunity is too strong, it can also cause damage to the body, leading to the occurrence of autoimmune diseases.
note that the immune system's defense of external organs after an organ transplant causes problems, making them need to be treated with immunosuppressants.
refore, chronic rejection and chronic immunosuppression of long-term complications (e.g. infection, malignant tumors, cardiovascular disease, etc.) are the key points to be solved, people are constantly looking for new treatment strategies.
BMJ published a study by the Petra Reinke team at The University of Berlin in Berlin called "Regulatory T cells forminimising immune suppression in transplantation: phase I/IIa clinicaltrial", which found that naturally regulated T-cells (nTreg) reduced immunosuppressant use in patients after kidney transplantation.
previous studies have found that nTreg has a therapeutic effect in patients after organ transplantation.
In this study, the researchers applied autolognation CD4, CD25, and FoxP3, nTreg to 11 patients who received a kidney transplant to observe its safety and ability, and to assess whether nTreg could reduce the amount of immunosuppressants in patients within 48 weeks of transplantation.
the safety of nTreg therapy after the use of immunosuppressants in patients after self-infusion minimized kidney transplantation.
dose-dependent toxicity was not found in all 3 nTreg treatment groups.
survival rate was 100% after allogeneic transplantation in the nTreg treatment group and the control group, and no serious adverse reaction events were reported.
the patients were biomarker analyzed by researchers in the nTreg treatment group and the control group, nTreg therapy had no significant effect on other immunocell subgroups compared to the control group.
analysis of biomarkers in patients in the nTreg treatment group and control group, this study shows that this nTreg is safer, has good tolerance, and can reduce the use of immunosuppressants.
Of course, in order to further improve the efficacy and stability of the therapy, more research is needed to explore the sustainable and functional transplantation of Tregs, specificity, and resistance to immunosuppressive drugs, and to study their optimal dose.
in the near future, patients with organ transplants can reduce the use of immunosuppressants by auto-transplanting immune cells to avoid their side effects.